443 related articles for article (PubMed ID: 30499732)
21. Prevalence and predictors of initiation of intrauterine devices and subdermal implants immediately after surgical abortion.
Roe AH; Fortin J; Janiak E; Maurer R; Goldberg AB
Contraception; 2019 Aug; 100(2):89-95. PubMed ID: 31082394
[TBL] [Abstract][Full Text] [Related]
22. Comparison of copper intrauterine device with levonorgestrel-bearing intrauterine system for post-abortion contraception.
Bilgehan F; Dilbaz B; Karadag B; Deveci CD
J Obstet Gynaecol Res; 2015 Sep; 41(9):1426-32. PubMed ID: 26180028
[TBL] [Abstract][Full Text] [Related]
23. A multicentre, open-label, randomised phase III study comparing a new levonorgestrel intrauterine contraceptive system (LNG-IUS 8) with combined oral contraception in young women of reproductive age.
Borgatta L; Buhling KJ; Rybowski S; Roth K; Rosen K
Eur J Contracept Reprod Health Care; 2016 Oct; 21(5):372-9. PubMed ID: 27494570
[TBL] [Abstract][Full Text] [Related]
24. Association Between Women's Use of Long-Acting Reversible Contraception and Declining Abortion Rates in New Zealand.
Whitley CE; Rose SB; Sim D; Cook H
J Womens Health (Larchmt); 2020 Jan; 29(1):21-28. PubMed ID: 31600111
[No Abstract] [Full Text] [Related]
25. Contraceptive method switching among women living in sub-Saharan Africa participating in an HIV-1 prevention trial: a prospective cohort study.
Chappell CA; Harkoo I; Szydlo DW; Bunge KE; Singh D; Nakabiito C; Mhlanga F; Kamira B; Piper JM; Balkus JE; Hillier SL;
Contraception; 2019 Sep; 100(3):214-218. PubMed ID: 31226323
[TBL] [Abstract][Full Text] [Related]
26. Long-acting reversible contraception in adolescents: a systematic review and meta-analysis.
Diedrich JT; Klein DA; Peipert JF
Am J Obstet Gynecol; 2017 Apr; 216(4):364.e1-364.e12. PubMed ID: 28038902
[TBL] [Abstract][Full Text] [Related]
27. Two-year continuation of intrauterine devices and contraceptive implants in a mixed-payer setting: a retrospective review.
Sanders JN; Turok DK; Gawron LM; Law A; Wen L; Lynen R
Am J Obstet Gynecol; 2017 Jun; 216(6):590.e1-590.e8. PubMed ID: 28188772
[TBL] [Abstract][Full Text] [Related]
28. Changes in body composition in women using long-acting reversible contraception.
Silva Dos Santos PN; Madden T; Omvig K; Peipert JF
Contraception; 2017 Apr; 95(4):382-389. PubMed ID: 28041992
[TBL] [Abstract][Full Text] [Related]
29. Acceptability of the levonorgestrel releasing-intrauterine system and etonogestrel implant: one-year results of an observational study.
Short M; Dallay D; Omokanye S; Hanisch JU; Inki P
Eur J Contracept Reprod Health Care; 2012 Feb; 17(1):79-88. PubMed ID: 22200172
[TBL] [Abstract][Full Text] [Related]
30. Long-term utilization and continuation of intrauterine devices.
Diedrich JT; Madden T; Zhao Q; Peipert JF
Am J Obstet Gynecol; 2015 Dec; 213(6):822.e1-6. PubMed ID: 26409157
[TBL] [Abstract][Full Text] [Related]
31. Long-acting reversible contraceptive (LARCs) methods.
Bahamondes L; Fernandes A; Monteiro I; Bahamondes MV
Best Pract Res Clin Obstet Gynaecol; 2020 Jul; 66():28-40. PubMed ID: 32014434
[TBL] [Abstract][Full Text] [Related]
32. Profiles of copper intrauterine devices and levonorgestrel intrauterine systems users in France in 2019: A national observational population-based study.
Roland N; Baricault B; Dray-Spira R; Weill A; Duranteau L; Zureik M
Int J Gynaecol Obstet; 2023 Feb; 160(2):594-603. PubMed ID: 36066002
[TBL] [Abstract][Full Text] [Related]
33. Rationale and enrollment results for a partially randomized patient preference trial to compare continuation rates of short-acting and long-acting reversible contraception.
Hubacher D; Spector H; Monteith C; Chen PL; Hart C
Contraception; 2015 Mar; 91(3):185-92. PubMed ID: 25500324
[TBL] [Abstract][Full Text] [Related]
34. Menstrual characteristics and ultrasonographic uterine cavity measurements predict bleeding and pain in nulligravid women using intrauterine contraception.
Kaislasuo J; Heikinheimo O; Lähteenmäki P; Suhonen S
Hum Reprod; 2015 Jul; 30(7):1580-8. PubMed ID: 25990577
[TBL] [Abstract][Full Text] [Related]
35. A 12-month multicenter, randomized study comparing the levonorgestrel intrauterine system with the etonogestrel subdermal implant.
Apter D; Briggs P; Tuppurainen M; Grunert J; Lukkari-Lax E; Rybowski S; Gemzell-Danielsson K
Fertil Steril; 2016 Jul; 106(1):151-157.e5. PubMed ID: 27016644
[TBL] [Abstract][Full Text] [Related]
36. Comparative contraceptive effectiveness of levonorgestrel-releasing and copper intrauterine devices: the European Active Surveillance Study for Intrauterine Devices.
Heinemann K; Reed S; Moehner S; Minh TD
Contraception; 2015 Apr; 91(4):280-3. PubMed ID: 25601350
[TBL] [Abstract][Full Text] [Related]
37. A multicenter randomized clinical trial of etonogestrel and levonorgestrel contraceptive implants with nonrandomized copper intrauterine device controls: effect on weight variations up to 3 years after placement.
Bahamondes L; Brache V; Ali M; Habib N;
Contraception; 2018 Sep; 98(3):181-187. PubMed ID: 29777663
[TBL] [Abstract][Full Text] [Related]
38. Continuation and satisfaction of reversible contraception.
Peipert JF; Zhao Q; Allsworth JE; Petrosky E; Madden T; Eisenberg D; Secura G
Obstet Gynecol; 2011 May; 117(5):1105-1113. PubMed ID: 21508749
[TBL] [Abstract][Full Text] [Related]
39. Profile of long-acting reversible contraception users in Europe.
Haimovich S
Eur J Contracept Reprod Health Care; 2009 Jun; 14(3):187-95. PubMed ID: 19565416
[TBL] [Abstract][Full Text] [Related]
40. Expanding long-acting contraceptive options: a prospective cohort study of the hormonal intrauterine device, copper intrauterine device, and implants in Nigeria and Zambia.
Brunie A; Stankevitz K; Nwala AA; Nqumayo M; Chen M; Danna K; Afolabi K; Rademacher KH
Lancet Glob Health; 2021 Oct; 9(10):e1431-e1441. PubMed ID: 34474001
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
